Japan Ends Full Coverage For COVID Therapeutics, Pharma Braces For Price Cuts

 
• By Lisa Takagi

Japan has started the stepped reduction of reimbursement of COVID-19 drugs under its national health insurance scheme, aiming to lower this to standard levels by April 2024. Oral antiviral Xocova also looks set to receive a one-off special price cut, over which the local industry has expressed its concerns.

Copayment for COVID therapeutics will be gradually higher for patients to reach the standard of Japan’s NHI scheme by April.
Co-payments for COVID therapeutics in Japan set to rise • Source: Shutterstock

More from Japan

More from Asia